Senju Pharmaceutical Co. v. Lupin Limited
780 F.3d 1337
Fed. Cir.2015Background
- Hatch-Waxman Act patent case from Delaware involving Senju, Lupin, and Hi-Tech over reexamined claims 6 and 12-16 of the '045 patent for gatifloxacin eye drops with EDTA.
- District Court found reexamined claims infringing but invalid for obviousness.
- Senju prevailed in prior Apotex litigations; reexamination occurred after those proceedings, with outcome that reexamined claims were granted.
- Lupin and Hi-Tech asserted collateral estoppel and non-infringement/invalidity counterclaims; district court reserved infringement/validity issues for trial.
- Reexamined claims include 6 (method to raise corneal permeability with 0.01% EDTA at pH 5–6), 12-16 (composition claims with EDTA 0.01% and gatifloxacin 0.3–0.8%), in the context of prior art.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Obviousness of reexamined claims 6 and 12-16. | Senju argues nonobviousness due to unexpected results and teaching away by prior art. | Lupin/Hi-Tech contend claims are obvious in view of prior fluoroquinolone patents and Grass/Rojanasakul. | Claims 12-16 obvious; claim 6 also found obvious in the district court’s framework. |
| Holistic analysis vs piecemeal reliance on Apotex 1 findings. | Senju says district court improperly reused Apotex 1 findings as terminal tests for the reexamined scope. | Lupin argues court properly analyzed reexamined claims as a whole with new evidence. | Court held proper holistic analysis incorporating reexamined claim scope. |
| Role of unexpected results in proving obviousness. | Senju asserts reexamination evidence showed unexpected efficacy of 0.01% EDTA at low pH. | Lupin contends unexpected results were unpersuasive and routine optimization. | Unexpected results not sufficient to rebut a strong case of obviousness; claims upheld as obvious. |
Key Cases Cited
- Interconnect Planning Corp. v. Feil, 774 F.2d 1132 (Fed. Cir. 1985) (district court must analyze reissue claims as a whole; avoid piecemeal analysis)
- Panduit Corp. v. Dennison Mfg. Co., 810 F.2d 1561 (Fed. Cir. 1987) (articulates evidence of nonobviousness and hindsight principles)
- KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398 (Sup. Ct. 2007) (obviousness standard: reason to combine plus reasonable expectation of success; not just teaching dispersal of known elements)
- Leo Pharma., Inc. v. Rea, 726 F.3d 1346 (Fed. Cir. 2013) (teaching-away and lack of a motivation to combine-damages obviousness analysis)
- Sciele Pharma Inc. v. Lupin Ltd., 684 F.3d 1253 (Fed. Cir. 2012) (clear and convincing evidence standard; district court’s factual credibility findings reviewed for clear error)